Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.662
Filtrar
1.
BMC Microbiol ; 24(1): 347, 2024 Sep 14.
Artículo en Inglés | MEDLINE | ID: mdl-39277715

RESUMEN

BACKGROUND: Linezolid-resistant Enterococcus faecium (LRE) is a global priority pathogen. Thirteen LRE were reported from clinical specimens between November 2021 and April 2023 at two laboratories in Karachi, Pakistan. We aimed to investigate the strain types and genes associated with linezolid resistance among these isolates. Whole genome sequencing (WGS) was performed and analyzed by multilocus sequence typing (MLST). The presence of linezolid resistance genes was identified using ResFinder v4.1.11 and the LRE-finder tool. RESULTS: Twelve isolates belonged to clonal complex 17 (CC17); ST80 (n = 10), ST612 (n = 1) and ST1380 (n = 1). Six isolates showed the presence of optrA gene and G2576T mutations in the 23S rRNA gene, while six showed poxtA and cfr(D) genes. One isolate showed the combination of optrA, cfr(D) and poxtA genes. CONCLUSION: Our findings show the circulation of CC17 sequence types with a known outbreak potential and we identified molecular mechanisms of resistance that were not previously reported from Pakistan.


Asunto(s)
Antibacterianos , Farmacorresistencia Bacteriana , Enterococcus faecium , Infecciones por Bacterias Grampositivas , Linezolid , Pruebas de Sensibilidad Microbiana , Tipificación de Secuencias Multilocus , Secuenciación Completa del Genoma , Enterococcus faecium/genética , Enterococcus faecium/efectos de los fármacos , Enterococcus faecium/aislamiento & purificación , Enterococcus faecium/clasificación , Pakistán , Linezolid/farmacología , Humanos , Antibacterianos/farmacología , Farmacorresistencia Bacteriana/genética , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/epidemiología , ARN Ribosómico 23S/genética , Femenino , Masculino , Genoma Bacteriano/genética , Genómica , Adulto , Proteínas Bacterianas/genética , Persona de Mediana Edad , Mutación
2.
Sci Rep ; 14(1): 20108, 2024 08 29.
Artículo en Inglés | MEDLINE | ID: mdl-39209935

RESUMEN

Clarithromycin (CLR) is currently a key antibiotic for Helicobacter pylori infection treatment, however, the data on CLR resistance patterns in Russia are missing. Here, we applied WGS-based approach to H. pylori clinical isolates from Russia to comprehensively investigate sequence variation, identify putative markers of CLR resistance and correlate them with phenotypic susceptibility testing. The phenotypic susceptibility of 44 H. pylori isolates (2014-2022) to CLR was determined by disc diffusion method: 23 isolates were CLR-resistant and 21-CLR-susceptible. All isolates were subjected to WGS and submitted to GenBank. Based on complete sequence analysis, we showed that among all sequence variants, the combination of mutations A2146G/A2147G in the 23S rRNA gene is the most reliable for prediction of phenotypic susceptibility. For the first time, the average number of mutations in 106 virulence-associated genes between resistant and susceptible groups were compared. Moreover, this study presents the first WGS insight into genetic diversity of H. pylori in Russia with a particular focus on the molecular basis of drug resistance: the novel mutations were described as potential markers for the resistance development. Of these, the most prominent was a frameshift deletion (252:CGGGT) in HP0820 coding region, which is a good candidate for further investigation.


Asunto(s)
Antibacterianos , Claritromicina , Farmacorresistencia Bacteriana , Infecciones por Helicobacter , Helicobacter pylori , Pruebas de Sensibilidad Microbiana , Secuenciación Completa del Genoma , Claritromicina/farmacología , Helicobacter pylori/genética , Helicobacter pylori/efectos de los fármacos , Federación de Rusia/epidemiología , Humanos , Farmacorresistencia Bacteriana/genética , Antibacterianos/farmacología , Secuenciación Completa del Genoma/métodos , Infecciones por Helicobacter/microbiología , Infecciones por Helicobacter/tratamiento farmacológico , Mutación , ARN Ribosómico 23S/genética , Genoma Bacteriano , Masculino , Variación Genética , Femenino , Adulto , Persona de Mediana Edad , Anciano
3.
Structure ; 32(9): 1429-1442.e6, 2024 Sep 05.
Artículo en Inglés | MEDLINE | ID: mdl-39019034

RESUMEN

Chloramphenicol (CHL) is an antibiotic targeting the peptidyl transferase center in bacterial ribosomes. We synthesized a new analog, CAM-BER, by substituting the dichloroacetyl moiety of CHL with a positively charged aromatic berberine group. CAM-BER suppresses bacterial cell growth, inhibits protein synthesis in vitro, and binds tightly to the 70S ribosome. Crystal structure analysis reveals that the bulky berberine group folds into the P site of the peptidyl transferase center (PTC), where it competes with the formyl-methionine residue of the initiator tRNA. Our toe-printing data confirm that CAM-BER acts as a translation initiation inhibitor in stark contrast to CHL, a translation elongation inhibitor. Moreover, CAM-BER induces a distinct rearrangement of conformationally restrained nucleotide A2059, suggesting that the 23S rRNA plasticity is significantly higher than previously thought. CAM-BER shows potential in avoiding CHL resistance and presents opportunities for developing novel berberine derivatives of CHL through medicinal chemistry exploration.


Asunto(s)
Berberina , Cloranfenicol , Ribosomas , Cloranfenicol/farmacología , Cloranfenicol/química , Cloranfenicol/metabolismo , Berberina/farmacología , Berberina/química , Berberina/análogos & derivados , Berberina/metabolismo , Ribosomas/metabolismo , Ribosomas/efectos de los fármacos , Cristalografía por Rayos X , Antibacterianos/farmacología , Antibacterianos/química , Modelos Moleculares , Escherichia coli/metabolismo , Escherichia coli/genética , Escherichia coli/efectos de los fármacos , Sitios de Unión , ARN Ribosómico 23S/metabolismo , ARN Ribosómico 23S/química , Peptidil Transferasas/metabolismo , Peptidil Transferasas/química , Biosíntesis de Proteínas/efectos de los fármacos , Conformación de Ácido Nucleico
4.
Am J Trop Med Hyg ; 111(3): 569-574, 2024 Sep 04.
Artículo en Inglés | MEDLINE | ID: mdl-39013372

RESUMEN

Flea-borne spotted fever and flea-borne (murine) typhus are rickettsioses caused by Rickettsia felis and Rickettsia typhi, respectively, and typically present as undifferentiated febrile illnesses. The relative contribution of these agents to flea-borne rickettsioses in California is unclear. We have developed a duplex reverse transcription real-time polymerase chain reaction (RT-rtPCR) assay targeting R. felis- and R. typhi-specific 23S ribosomal RNA single nucleotide polymorphisms to better understand the respective roles of these agents in causing flea-borne rickettsioses in California. This assay was compared with an established duplex R. felis- and R. typhi-ompB rt-PCR assay and was shown to have 1,000-fold and 10-fold greater analytical sensitivity for the detection of R. felis and R. typhi, respectively. Retrospective testing of clinical specimens with both assays established R. typhi as the major etiologic agent of flea-borne rickettsioses in California.


Asunto(s)
Polimorfismo de Nucleótido Simple , ARN Ribosómico 23S , Infecciones por Rickettsia , Siphonaptera , Humanos , Siphonaptera/microbiología , Animales , Infecciones por Rickettsia/microbiología , Infecciones por Rickettsia/diagnóstico , Infecciones por Rickettsia/epidemiología , ARN Ribosómico 23S/genética , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Rickettsia typhi/genética , Rickettsia typhi/aislamiento & purificación , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Rickettsia felis/genética , Rickettsia felis/aislamiento & purificación , Sensibilidad y Especificidad , California/epidemiología , Estudios Retrospectivos
5.
Eur J Clin Microbiol Infect Dis ; 43(9): 1825-1835, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39017999

RESUMEN

PURPOSE: To investigate macrolide-resistant Mycobacterium pneumoniae (MRMP) pneumonia in children and construct a logistic regression model for mutations in the Mycoplasma pneumoniae drug-resistant gene. METHODS: Clinical data of 281 children were analyzed. Sequencing confirmed a mutation at the A2063G locus of the 23 S rRNA gene in 227 children (A2063G group); 54 children showed no mutations (non-MRMP [NMRMP] group). We compared clinical features, laboratory tests, imaging, and bronchoscopy results and constructed a multifactorial logistic regression model to analyze risk and protective factors. RESULTS: The A2063G group had longer durations of fever and hospitalization before admission, a higher proportion of treatment with sodium methylprednisolone succinate (MPS)/dexamethasone, longer time to discontinue hormones, and higher probability of combined infections. Monocyte percentage was significantly higher in the A2063G group. Imaging suggested a higher incidence of infections in the right lung compared to both lungs. Univariate analysis revealed fever duration before admission, hormone dose and duration, monocyte percentage, and mixed infections as risk factors for Mycoplasma pneumoniae infection with the A2063G mutation. The logistic regression model showed that mixed infections were an independent risk factor for the A2063G locus mutation, whereas hormone dose was a protective factor. CONCLUSION: A prevalence of macrolide resistance of 80.8% among children was observed in the region. Logistic regression analysis revealed that co-infection with other respiratory pathogens is an independent risk factor for the development of resistance genes, while the use of hormone dosage acts as a protective factor.


Asunto(s)
Antibacterianos , Farmacorresistencia Bacteriana , Macrólidos , Mycoplasma pneumoniae , Neumonía por Mycoplasma , ARN Ribosómico 23S , Humanos , Neumonía por Mycoplasma/microbiología , Neumonía por Mycoplasma/tratamiento farmacológico , Neumonía por Mycoplasma/epidemiología , Mycoplasma pneumoniae/genética , Mycoplasma pneumoniae/efectos de los fármacos , Macrólidos/farmacología , Macrólidos/uso terapéutico , Femenino , Masculino , Farmacorresistencia Bacteriana/genética , Preescolar , Niño , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , ARN Ribosómico 23S/genética , Modelos Logísticos , Lactante , Mutación , Factores de Riesgo , Estudios Retrospectivos
6.
RNA ; 30(10): 1264-1276, 2024 Sep 16.
Artículo en Inglés | MEDLINE | ID: mdl-39043438

RESUMEN

Ribosomal RNAs are transcribed as part of larger precursor molecules. In Escherichia coli, complementary RNA segments flank each rRNA and form long leader-trailer (LT) helices, which are crucial for subunit biogenesis in the cell. A previous study of 15 representative species suggested that most but not all prokaryotes contain LT helices. Here, we use a combination of in silico folding and covariation methods to identify and characterize LT helices in 4464 bacterial and 260 archaeal organisms. Our results suggest that LT helices are present in all phyla, including Deinococcota, which had previously been suspected to lack LT helices. In very few organisms, our pipeline failed to detect LT helices for both 16S and 23S rRNA. However, a closer case-by-case look revealed that LT helices are indeed present but escaped initial detection. Over 3600 secondary structure models, many well supported by nucleotide covariation, were generated. These structures show a high degree of diversity. Yet, all exhibit extensive base-pairing between the leader and trailer strands, in line with a common and essential function.


Asunto(s)
Archaea , Conformación de Ácido Nucleico , ARN de Archaea , ARN Bacteriano , ARN de Archaea/genética , ARN de Archaea/química , ARN de Archaea/metabolismo , Archaea/genética , ARN Bacteriano/genética , ARN Bacteriano/química , ARN Bacteriano/metabolismo , ARN Ribosómico/genética , ARN Ribosómico/química , ARN Ribosómico/metabolismo , Bacterias/genética , Precursores del ARN/genética , Precursores del ARN/metabolismo , Precursores del ARN/química , ARN Ribosómico 23S/genética , ARN Ribosómico 23S/química , ARN Ribosómico 23S/metabolismo , Secuencia de Bases , ARN Ribosómico 16S/genética , ARN Ribosómico 16S/química , Emparejamiento Base
7.
Proc Natl Acad Sci U S A ; 121(32): e2401981121, 2024 Aug 06.
Artículo en Inglés | MEDLINE | ID: mdl-39078675

RESUMEN

Dihydrouridine (D), a prevalent and evolutionarily conserved base in the transcriptome, primarily resides in tRNAs and, to a lesser extent, in mRNAs. Notably, this modification is found at position 2449 in the Escherichia coli 23S rRNA, strategically positioned near the ribosome's peptidyl transferase site. Despite the prior identification, in E. coli genome, of three dihydrouridine synthases (DUS), a set of NADPH and FMN-dependent enzymes known for introducing D in tRNAs and mRNAs, characterization of the enzyme responsible for D2449 deposition has remained elusive. This study introduces a rapid method for detecting D in rRNA, involving reverse transcriptase-blockage at the rhodamine-labeled D2449 site, followed by PCR amplification (RhoRT-PCR). Through analysis of rRNA from diverse E. coli strains, harboring chromosomal or single-gene deletions, we pinpoint the yhiN gene as the ribosomal dihydrouridine synthase, now designated as RdsA. Biochemical characterizations uncovered RdsA as a unique class of flavoenzymes, dependent on FAD and NADH, with a complex structural topology. In vitro assays demonstrated that RdsA dihydrouridylates a short rRNA transcript mimicking the local structure of the peptidyl transferase site. This suggests an early introduction of this modification before ribosome assembly. Phylogenetic studies unveiled the widespread distribution of the yhiN gene in the bacterial kingdom, emphasizing the conservation of rRNA dihydrouridylation. In a broader context, these findings underscore nature's preference for utilizing reduced flavin in the reduction of uridines and their derivatives.


Asunto(s)
Escherichia coli , Escherichia coli/genética , Escherichia coli/metabolismo , ARN Ribosómico 23S/metabolismo , ARN Ribosómico 23S/genética , ARN Ribosómico 23S/química , Uridina/análogos & derivados , Uridina/metabolismo , Uridina/química , Proteínas de Escherichia coli/metabolismo , Proteínas de Escherichia coli/genética , Proteínas de Escherichia coli/química , ARN Bacteriano/metabolismo , ARN Bacteriano/genética , ARN Bacteriano/química
8.
RNA Biol ; 21(1): 31-41, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38952121

RESUMEN

Large ribosomal RNAs (rRNAs) are modified heavily post-transcriptionally in functionally important regions but, paradoxically, individual knockouts (KOs) of the modification enzymes have minimal impact on Escherichia coli growth. Furthermore, we recently constructed a strain with combined KOs of five modification enzymes (RluC, RlmKL, RlmN, RlmM and RluE) of the 'critical region' of the peptidyl transferase centre (PTC) in 23S rRNA that exhibited only a minor growth defect at 37°C (although major at 20°C). However, our combined KO of modification enzymes RluC and RlmE (not RluE) resulted in conditional lethality (at 20°C). Although the growth rates for both multiple-KO strains were characterized, the molecular explanations for such deficits remain unclear. Here, we pinpoint biochemical defects in these strains. In vitro fast kinetics at 20°C and 37°C with ribosomes purified from both strains revealed, counterintuitively, the slowing of translocation, not peptide bond formation or peptidyl release. Elongation rates of protein synthesis in vivo, as judged by the kinetics of ß-galactosidase induction, were also slowed. For the five-KO strain, the biggest deficit at 37°C was in 70S ribosome assembly, as judged by a dominant 50S peak in ribosome sucrose gradient profiles at 5 mM Mg2+. Reconstitution of this 50S subunit from purified five-KO rRNA and ribosomal proteins supported a direct role in ribosome biogenesis of the PTC region modifications per se, rather than of the modification enzymes. These results clarify the importance and roles of the enigmatic rRNA modifications.


Asunto(s)
Proteínas de Escherichia coli , Escherichia coli , Peptidil Transferasas , Biosíntesis de Proteínas , ARN Ribosómico , Ribosomas , Peptidil Transferasas/metabolismo , Peptidil Transferasas/genética , Escherichia coli/genética , Escherichia coli/metabolismo , Ribosomas/metabolismo , Proteínas de Escherichia coli/metabolismo , Proteínas de Escherichia coli/genética , ARN Ribosómico/genética , ARN Ribosómico/metabolismo , ARN Ribosómico 23S/metabolismo , ARN Ribosómico 23S/genética , Cinética
9.
Zhonghua Yu Fang Yi Xue Za Zhi ; 58(7): 1035-1040, 2024 Jul 06.
Artículo en Chino | MEDLINE | ID: mdl-39034788

RESUMEN

To analyze the infection and drug-resistant gene 23S rRNA mutations of mycoplasma pneumoniae (Mp) in hospitalized children aged 0-17 in Ningbo City from 2019 to 2023. Throat swabs were collected from hospitalized children with respiratory tract infections in Ningbo University Affiliated Women and Children's Hospital from 2019 to 2023. They were subjected to real-time fluorescence quantitative polymerase chain reaction detection to analyze Mp infection and drug-resistant gene (23S rRNA) mutations. Intergroup comparisons were made by the Chi-square test or Fisher's exact probability method. A total of 18 968 hospitalized children were included, with a total positive rate of 30.37% (5 760/18 968). The total positive rate of drug-resistant gene mutations was 82.45% (4 749/5 760). The positive rate of Mp in male children was 29.26%, which was lower than that in female children (31.67%, χ2=12.948, P<0.001). The positive rate of Mp drug-resistant gene mutations in male children was 82.52%, which was higher than that in female children(82.37%, χ2=0.021, P=0.885). The positive rates of Mp increased with age (χ2=1 722.21, P<0.001). The positive rates of Mp drug-resistant gene mutations also increased with age (χ2=13.152, P<0.001). In the four seasons, the total positive rate of Mp in summer and autumn was significantly higher than that in winter and spring (χ2=1 085.149, P<0.001). Among them, the Mp positive rates in the summer and autumn of 2019 were as high as 38.26% and 34.49%, while in the summer and autumn of 2020, the Mp positive rates were 2.55% and 1.65%, respectively, which were the lowest in previous years. In the summer and autumn of 2023, the Mp positive rates increased to 47.22% and 51.06%. There was no statistically significant difference in the detection rate of Mp drug-resistant gene mutations among the four seasons. In Conclusion, Mp infection was more prevalent in the summer and autumn in Ningbo city and females and children aged 7-17 were more susceptible. The epidemic of Mp infection in Ningbo occurred in the summer of 2019. After the COVID-19 pandemic in 2020, the positive rate of Mp rapidly decreased and later remained in a low incidence state. After the lifting of restrictive prevention and control measures in 2023, the Mp positive rate returned to an epidemic state. The positive rate of Mp drug-resistant gene (23S rRNA) mutations was relatively high.


Asunto(s)
Farmacorresistencia Bacteriana , Mutación , Mycoplasma pneumoniae , Neumonía por Mycoplasma , Humanos , Niño , Lactante , Preescolar , Femenino , Masculino , Mycoplasma pneumoniae/genética , Adolescente , Neumonía por Mycoplasma/epidemiología , Neumonía por Mycoplasma/microbiología , Farmacorresistencia Bacteriana/genética , ARN Ribosómico 23S/genética , Infecciones del Sistema Respiratorio/microbiología , Infecciones del Sistema Respiratorio/epidemiología , Recién Nacido , China/epidemiología , Antibacterianos/farmacología , Antibacterianos/uso terapéutico
10.
Gut Microbes ; 16(1): 2379439, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39052777

RESUMEN

Efflux pumps play a crucial role in the development of antibiotic resistance. The aim of this study was to investigate the relationship between efflux pump gene expression and resistance gene mutations in Helicobacter pylori. Twenty-six clinical strains with varying resistance characteristics were selected for further experiment. Seven susceptible strains were induced to become resistant, and the expression of efflux pump genes and point mutations were recorded. Four susceptible strains were selected to undergo candidate mutation construction, and changes in efflux pump gene expression were detected. Efflux pump knockout strains were constructed, and their effects on preventing and reversing antibiotic resistance gene mutations were assessed. Results showed that the expression of efflux pump genes hefA and hefD was significantly higher in the multidrug-resistant group compared to other groups. During the process of antibiotic-induced resistance, efflux pump gene expression did not exhibit a steady increase or decrease. Strains with the A2143G or A2142G point mutations in 23S rRNA exhibited lower hefA gene expression. Strains with mutations at 87K/91N, 87N/91 G, 87K/91D, or 87N/91Y in gyrA and the 194insertA mutation in rdxA showed higher hefA gene expression compared to the wild-type strain. During the process of antibiotic-induced resistance, the strain with the knockout of the efflux pump gene hefA developed mutations in the 23S rRNA, gyrA, or rdxA genes later compared to the wild-type strain. Knockout of the efflux pump gene could reverse the phenotypic resistance to clarithromycin or metronidazole in some strains but had no effect on reverse resistance gene mutation. This study suggested that different resistance gene point mutations may have varying effects on efflux pump gene expression. Knockout of the efflux pump gene can delay or prevent antibiotic resistance gene mutations to some extent and can reverse phenotypic resistance to clarithromycin and metronidazole in certain strains.


Asunto(s)
Antibacterianos , Proteínas Bacterianas , Infecciones por Helicobacter , Helicobacter pylori , Proteínas de Transporte de Membrana , Helicobacter pylori/genética , Helicobacter pylori/efectos de los fármacos , Helicobacter pylori/metabolismo , Antibacterianos/farmacología , Proteínas de Transporte de Membrana/genética , Proteínas de Transporte de Membrana/metabolismo , Infecciones por Helicobacter/microbiología , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Humanos , Farmacorresistencia Bacteriana/genética , Mutación Puntual , Mutación , Pruebas de Sensibilidad Microbiana , Regulación Bacteriana de la Expresión Génica , Farmacorresistencia Bacteriana Múltiple/genética , ARN Ribosómico 23S/genética , Girasa de ADN/genética , Girasa de ADN/metabolismo
11.
BMC Infect Dis ; 24(1): 758, 2024 Jul 31.
Artículo en Inglés | MEDLINE | ID: mdl-39085799

RESUMEN

BACKGROUND: The global prospective surveillance data showed the re-emergence of mycoplasma pneumoniae pneumonia (MPP) in Europe and Asia after the coronavirus disease 2019 pandemic. We sought to observe the effect of macrolide antibiotics in the treatment of MPP carrying a macrolide-resistant mutation gene and the potential of targeted next-generation sequencing (tNGS) as a front-line diagnostic in MPP patients. METHODS: The baseline characteristics of 91 children with MPP hospitalized from January to October 2023 were retrospectively analyzed. They were divided into two groups according to whether carrying the macrolide-resistant mutation or not. The logistic and linear regression analyses were used to determine whether the mutation was a standalone predictive predictor of the duration of fever and hospital length of stay. RESULTS: First, no patients had a fever for ≥ 7 days after macrolide treatment. But length of stay and hormone concentration were significantly different between the two groups (P < 0.05). There were also no statistical association between the mutation and the duration of fever and hospital length of stay. CONCLUSION: Macrolides can be administered to MPP children carrying a macrolide-resistant mutation. tNGS can be seen as a front-line diagnostic in MPP.


Asunto(s)
Antibacterianos , Farmacorresistencia Bacteriana , Macrólidos , Mutación , Mycoplasma pneumoniae , Neumonía por Mycoplasma , ARN Ribosómico 23S , Humanos , Neumonía por Mycoplasma/tratamiento farmacológico , Neumonía por Mycoplasma/microbiología , Macrólidos/uso terapéutico , Macrólidos/farmacología , Mycoplasma pneumoniae/genética , Mycoplasma pneumoniae/efectos de los fármacos , Femenino , Masculino , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Preescolar , Niño , Farmacorresistencia Bacteriana/genética , Estudios Retrospectivos , ARN Ribosómico 23S/genética , Lactante , Tiempo de Internación , Resultado del Tratamiento , Secuenciación de Nucleótidos de Alto Rendimiento
12.
Indian J Med Microbiol ; 50: 100652, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38906329

RESUMEN

PURPOSE: In India there is evidence of antimicrobial resistance in Helicobacter pylori, a definitive pathobiont whose only known niche is human gastric mucosa. This in turn can lead to failure of treatment, persistence or chronicity of infection. This hospital based, prospective, observational study investigates the presence of antimicrobial resistance in the organism with focus on detection of A2143G and A2142G major point mutations in domain V of H. pylori 23S rRNA gene as a molecular mechanism of conferring resistance. METHODS: Endoscopic gastric biopsy samples from 52 patients presenting with dyspeptic symptoms from January 2016 to December 2016 were subjected to culture in a microaerophilic environment using Campylobacter agar with for 2-5 days. Isolates were identified using gram-staining, motility test and biochemical reactions. Modified Kirby-Bauer Disc diffusion method was used to determine antimicrobial susceptibility against Clarithromycin, Metronidazole, Amoxycillin, Levofloxacin, Tetracycline, Cotrimoxazole and Erythromycin. Additionally, detection of A2143G and A2142G point mutations conferring Clarithromycin resistance was carried out using real time PCR following extraction and quantification of bacterial DNA. Histopathological examination was carried out on all biopsy samples. Descriptive and inferential statistical analytical methods were used. Differences were considered significant for p < 0.05. RESULTS: Culture positivity for H. pylori by phenotypic method was found to be 36.54%. Histopathologic Examination detected H. pylori in 55.7% and PCR detected 48.08% for either the wild type or one of two mutant strains A2143G and A2142G. No sample was found positive for both mutations. Metronidazole showed the highest resistance among antibiotics (78.9%) followed by Clarithromycin (47.3%). CONCLUSION: Prevalence of antimicrobial resistance in H. pylori in North-Eastern India is substantially high with A2143G mutation being clinically most important in conferring Clarithromycin resistance. This resistance might be associated with low eradication rates despite initiation of therapy. ROC analysis of PCR proved it to be a good diagnostic tool.


Asunto(s)
Antibacterianos , Claritromicina , Farmacorresistencia Bacteriana , Dispepsia , Infecciones por Helicobacter , Helicobacter pylori , Pruebas de Sensibilidad Microbiana , Mutación Puntual , ARN Ribosómico 23S , Humanos , Helicobacter pylori/genética , Helicobacter pylori/efectos de los fármacos , Helicobacter pylori/aislamiento & purificación , ARN Ribosómico 23S/genética , India , Infecciones por Helicobacter/microbiología , Infecciones por Helicobacter/diagnóstico , Antibacterianos/farmacología , Estudios Prospectivos , Farmacorresistencia Bacteriana/genética , Claritromicina/farmacología , Masculino , Femenino , Adulto , Persona de Mediana Edad , Dispepsia/microbiología , Anciano , Adulto Joven , Biopsia
13.
PLoS One ; 19(6): e0305720, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38905249

RESUMEN

Syphilis, caused by Treponema pallidum, is resurging globally. Molecular typing allows for the investigation of its epidemiology. In Pakistan and other nations, T. pallidum subsp. pallidum has developed widespread macrolide resistance in the past decade. A study at the Peshawar Regional Blood Centre from June 2020-June 2021 analyzed serum samples from 32,812 blood donors in Khyber Pakhtunkhwa, Pakistan, to assess circulating T. pallidum strains and antibiotic resistance. Blood samples were initially screened for T. pallidum antibodies using a chemiluminescent microparticle immunoassay (CMIA). CMIA-reactive samples underwent polymerase chain reaction (PCR) targeted the polA, tpp47, bmp, and tp0319 genes. PCR-positive samples were further analyzed for molecular subtyping using a CDC-developed procedure and tp0548 gene examination. All PCR-positive samples were analyzed for the presence of point mutations A2058G and A2059G in 23S rRNA, as well as the G1058C mutation in 16S rRNA. These mutations are known to impart antimicrobial resistance to macrolides and doxycycline, respectively. Out of 32,812 serum samples, 272 (0.83%) were CMIA-reactive, with 46 being PCR-positive. Nine T. pallidum subtypes were identified, predominantly 14d/f. The A2058G mutation in 23S rRNA was found in 78% of cases, while G1058C in 16S rRNA and A2059G in 23S rRNA were absent. The research found donor blood useful for assessing T. pallidum molecular subtypes and antibiotic resistance, especially when chancres are not present. The prevalent subtype was 14d/f (51.85%), and the high macrolide resistance of 36 (78%) indicates caution in using macrolides for syphilis treatment in Khyber Pakhtunkhwa, Pakistan.


Asunto(s)
Antibacterianos , Donantes de Sangre , Farmacorresistencia Bacteriana , Sífilis , Treponema pallidum , Treponema pallidum/genética , Treponema pallidum/efectos de los fármacos , Treponema pallidum/aislamiento & purificación , Humanos , Pakistán/epidemiología , Sífilis/microbiología , Sífilis/epidemiología , Sífilis/sangre , Sífilis/tratamiento farmacológico , Antibacterianos/farmacología , Farmacorresistencia Bacteriana/genética , Masculino , Femenino , Adulto , Macrólidos/farmacología , ARN Ribosómico 23S/genética , ARN Ribosómico 16S/genética , Persona de Mediana Edad , Doxiciclina/farmacología , Doxiciclina/uso terapéutico , Adulto Joven
14.
Microbiol Spectr ; 12(8): e0361523, 2024 Aug 06.
Artículo en Inglés | MEDLINE | ID: mdl-38904371

RESUMEN

To analyze the characteristics of Mycoplasma pneumoniae as well as macrolide antibiotic resistance through whole-genome sequencing and comparative genomics. Thirteen clinical strains isolated from 2003 to 2019 were selected, 10 of which were resistant to erythromycin (MIC >64 µg/mL), including 8 P1-type I and 2 P1-type II. Three were sensitive (<1 µg/mL) and P1-type II. One resistant strain had an A→G point mutation at position 2064 in region V of the 23S rRNA, the others had it at position 2063, while the three sensitive strains had no mutation here. Genome assembly and comparative genome analysis revealed a high level of genome consistency within the P1 type, and the primary differences in genome sequences concentrated in the region encoding the P1 protein. In P1-type II strains, three specific gene mutations were identified: C162A and A430G in L4 gene and T1112G mutation in the CARDS gene. Clinical information showed seven cases were diagnosed with severe pneumonia, all of which were infected with drug-resistant strains. Notably, BS610A4 and CYM219A1 exhibited a gene multi-copy phenomenon and shared a conserved functional domain with the DUF31 protein family. Clinically, the patients had severe refractory pneumonia, with pleural effusion, necessitating treatment with glucocorticoids and bronchoalveolar lavage. The primary variations between strains occur among different P1-types, while there is a high level of genomic consistency within P1-types. Three mutation loci associated with specific types were identified, and no specific genetic alterations directly related to clinical presentation were observed.IMPORTANCEMycoplasma pneumoniae is an important pathogen of community-acquired pneumonia, and macrolide resistance brings difficulties to clinical treatment. We analyzed the characteristics of M. pneumoniae as well as macrolide antibiotic resistance through whole-genome sequencing and comparative genomics. The work addressed primary variations between strains that occur among different P1-types, while there is a high level of genomic consistency within P1-types. In P1-type II strains, three specific gene mutations were identified: C162A and A430G in L4 gene and T1112G mutation in the CARDS gene. All the strains isolated from severe pneumonia cases were drug-resistant, two of which exhibited a gene multi-copy phenomenon, sharing a conserved functional domain with the DUF31 protein family. Three mutation loci associated with specific types were identified, and no specific genetic alterations directly related to clinical presentation were observed.


Asunto(s)
Antibacterianos , Farmacorresistencia Bacteriana , Genoma Bacteriano , Pruebas de Sensibilidad Microbiana , Mycoplasma pneumoniae , Neumonía por Mycoplasma , Mycoplasma pneumoniae/genética , Mycoplasma pneumoniae/efectos de los fármacos , Mycoplasma pneumoniae/clasificación , Mycoplasma pneumoniae/aislamiento & purificación , Humanos , Antibacterianos/farmacología , Genoma Bacteriano/genética , Neumonía por Mycoplasma/microbiología , Neumonía por Mycoplasma/tratamiento farmacológico , Farmacorresistencia Bacteriana/genética , Masculino , Femenino , Secuenciación Completa del Genoma , Persona de Mediana Edad , Macrólidos/farmacología , Adulto , Mutación , ARN Ribosómico 23S/genética , Genómica , Anciano , Eritromicina/farmacología
15.
Microb Genom ; 10(6)2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38847800

RESUMEN

Sequence comparison of 16S rRNA PCR amplicons is an established approach to taxonomically identify bacterial isolates and profile complex microbial communities. One potential application of recent advances in long-read sequencing technologies is to sequence entire rRNA operons and capture significantly more phylogenetic information compared to sequencing of the 16S rRNA (or regions thereof) alone, with the potential to increase the proportion of amplicons that can be reliably classified to lower taxonomic ranks. Here we describe GROND (Genome-derived Ribosomal Operon Database), a publicly available database of quality-checked 16S-ITS-23S rRNA operons, accompanied by multiple taxonomic classifications. GROND will aid researchers in analysis of their data and act as a standardised database to allow comparison of results between studies.


Asunto(s)
Bacterias , Filogenia , ARN Ribosómico 16S , ARN Ribosómico 16S/genética , Bacterias/genética , Bacterias/clasificación , ARN Ribosómico 23S/genética , Operón , Operón de ARNr/genética , Bases de Datos Genéticas , Bases de Datos de Ácidos Nucleicos , Análisis de Secuencia de ADN/métodos
16.
Braz J Microbiol ; 55(3): 2101-2105, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38748394

RESUMEN

Syphilis remains a significant public health concern, with serological assays being the primary method for diagnosis. However, molecular techniques have proven to be reliable tools for the diagnosis and understanding of the transmission dynamics of Treponema pallidum infection. This study aimed to evaluate the efficacy of syphilis treatment using molecular assays, perform Enhanced Centers for Disease Control and Prevention (ECDC) typing, and analyze resistance (macrolide and doxycycline) in the T. pallidum isolate. PCR assay amplified treponemal DNA only from the lesion sample, whereas qPCR was able to amplify DNA in both lesion and blood samples before treatment. Throughout the treatment follow-up, qPCR effectively did not identify treponemal DNA in the blood for up to one to two weeks after treatment. ECDC typing revealed the genotype 14 e/g in the Brazilian T. pallidum isolate, and the presence of the A2058G mutation in 23 S rRNA gene, indicating macrolide resistance. Although, the G1058C mutation in 16 S rRNA gene was not detected. Notably, qPCR demonstrated its potential for diagnosing T. pallidum in blood samples, even when the treponemal DNA levels were low, enabling more accurate and sensitive diagnosis and guiding better syphilis therapy. In addition, to the best of our knowledge, this study represents the first identification of subtype 14 e/g and azithromycin resistance in a Brazilian T. pallidum isolate.


Asunto(s)
Antibacterianos , Sífilis , Treponema pallidum , Treponema pallidum/genética , Treponema pallidum/aislamiento & purificación , Treponema pallidum/clasificación , Treponema pallidum/efectos de los fármacos , Sífilis/microbiología , Sífilis/diagnóstico , Sífilis/tratamiento farmacológico , Humanos , Brasil , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Genotipo , Farmacorresistencia Bacteriana/genética , ADN Bacteriano/genética , Masculino , Macrólidos/farmacología , Tipificación Molecular/métodos , Doxiciclina/uso terapéutico , Adulto , ARN Ribosómico 23S/genética , Estudios de Seguimiento
17.
J Glob Antimicrob Resist ; 38: 21-26, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38719188

RESUMEN

OBJECTIVES: Linezolid-resistant opportunistic human pathogens Enterococcus faecalis and Enterococcus faecium are emerging health threats as limited therapeutic options remain. The aim of this study was to investigate the epidemiology, resistance mechanisms, and genetic diversity of linezolid-resistant enterococci (LRE) isolated between 2013 and 2021 and received at the Belgian National Reference Centre (NRC) for Enterococci. METHODS: Linezolid susceptibility testing was performed upon request on 2458 submitted enterococci strains. Whole-genome sequencing was performed on all LRE strains. RESULTS: Seventy-eight LRE human isolates, of which 63 (81%) E. faecalis and 15 (19%) E. faecium strains, were submitted to the Belgian NRC for Enterococci. Of the linezolid-resistant E. faecalis strains, 97% harboured the optrA gene (56% wild-type pE349) and 3% the poxtA gene. Of the linezolid-resistant E. faecium strains, 54% harboured the G2576T point mutation in the V domain of the 23S rRNA genes, 23% the poxtA, and 23% the optrA gene. Furthermore, two E. faecium strains were identified with a combination of two resistance mechanisms ([i] optrA and poxtA, and [ii] cfr(B) and G2576T point mutation, respectively). Vancomycin resistance was observed in 15% (n = 12) of the LRE. ST480 (n = 42/63 typed strains, 67%) was the most frequently detected sequence type (ST) in linezolid-resistant E. faecalis strains, while ST203 (n = 5/15 typed strains, 33%) was the most frequently detected ST in linezolid-resistant E. faecium strains. CONCLUSIONS: E. faecalis isolates harbouring optrA were the predominant LRE in Belgium, with ST480 as the most prominent multilocus sequence typing. Linezolid resistance in E. faecium could be attributed to either chromosomal mutations or transferable resistance determinants.


Asunto(s)
Antibacterianos , Farmacorresistencia Bacteriana , Enterococcus faecalis , Enterococcus faecium , Variación Genética , Infecciones por Bacterias Grampositivas , Linezolid , Pruebas de Sensibilidad Microbiana , Secuenciación Completa del Genoma , Linezolid/farmacología , Humanos , Bélgica/epidemiología , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/epidemiología , Enterococcus faecalis/genética , Enterococcus faecalis/efectos de los fármacos , Enterococcus faecalis/aislamiento & purificación , Enterococcus faecium/genética , Enterococcus faecium/efectos de los fármacos , Enterococcus faecium/aislamiento & purificación , Antibacterianos/farmacología , Anciano , Femenino , Masculino , Persona de Mediana Edad , Adulto , Anciano de 80 o más Años , Adulto Joven , Adolescente , Niño , Preescolar , ARN Ribosómico 23S/genética , Lactante
18.
BMC Infect Dis ; 24(1): 486, 2024 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-38730362

RESUMEN

BACKGROUND: Recently, linezolid-resistant staphylococci have become an emerging problem worldwide. Understanding the mechanisms of resistance, molecular epidemiology and transmission of linezolid-resistant CoNS in hospitals is very important. METHODS: The antimicrobial susceptibilities of all isolates were determined by the microdilution method. The resistance mechanisms and molecular characteristics of the strains were determined using whole-genome sequencing and PCR. RESULTS: All the strains were resistant to oxacillin and carried the mecA gene; 13 patients (36.1%) had prior linezolid exposure. Most S. epidermidis and S. hominis isolates were ST22 and ST1, respectively. MLST typing and evolutionary analysis indicated most linezolid-resistant CoNS strains were genetically related. In this study, we revealed that distinct CoNS strains have different mechanisms of linezolid resistance. Among ST22-type S. epidermidis, acquisition of the T2504A and C2534T mutations in the V domain of the 23 S rRNA gene, as well as mutations in the ribosomal proteins L3 (L101V, G152D, and D159Y) and L4 (N158S), were linked to the development of linezolid resistance. In S. cohnii isolates, cfr, S158Y and D159Y mutations in the ribosomal protein L3 were detected. Additionally, emergence of the G2576T mutation and the cfr gene were major causes of linezolid resistance in S. hominis isolates. The cfr gene, G2576T and C2104T mutations, M156T change in L3 protein, and I188S change in L4 protein were found in S. capitis isolates. CONCLUSION: The emergence of linezolid-resistant CoNS in the environment is concerning because it involves clonal dissemination and frequently coexists with various drug resistance mechanisms.


Asunto(s)
Antibacterianos , Linezolid , Pruebas de Sensibilidad Microbiana , Infecciones Estafilocócicas , Centros de Atención Terciaria , Linezolid/farmacología , Humanos , China/epidemiología , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/epidemiología , Antibacterianos/farmacología , Femenino , Masculino , Persona de Mediana Edad , Tipificación de Secuencias Multilocus , Anciano , Secuenciación Completa del Genoma , Staphylococcus/efectos de los fármacos , Staphylococcus/genética , Staphylococcus/clasificación , Staphylococcus/enzimología , Coagulasa/metabolismo , Coagulasa/genética , ARN Ribosómico 23S/genética , Adulto , Resistencia a la Meticilina/genética , Mutación , Proteínas Bacterianas/genética
19.
Helicobacter ; 29(3): e13084, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38717034

RESUMEN

BACKGROUND: Recently, a simple tailored therapy based on clarithromycin resistance has been implemented as Helicobacter pylori (H. pylori) eradication therapy. Nonetheless, despite the tailored therapy and frequent adverse events, studies on treatment period are lacking. This study aimed to compare the H. pylori eradication rates of 7-day and 14-day tailored therapy regimens according to clarithromycin resistance. MATERIALS AND METHODS: This multicenter, prospective, randomized, noninferiority trial enrolled H. pylori-positive patients who were randomly assigned to 7-day and 14-day regimen groups, depending on the presence or absence of clarithromycin resistance by 23S rRNA gene point mutations. Standard triple therapy (STT) (20 mg rabeprazole, 1 g amoxicillin, and 500 mg clarithromycin twice daily) or bismuth quadruple therapy (BQT) (20 mg rabeprazole twice daily, 500 mg metronidazole thrice daily, 120 mg bismuth four times daily, and 500 mg tetracycline four times daily) was assigned by clarithromycin resistance. Eradication rates and adverse events were evaluated. RESULTS: A total of 314 and 278 patients were included in the intention-to-treat (ITT) and per-protocol (PP) analyses, respectively; however, 31 patients were lost to follow-up, whereas five patients violated the protocol. Both the 7-day and 14-day regimens showed similar eradication rates in the ITT (7-day vs. 14-day: 78.3% vs. 78.3%, p > 0.99) and PP (87.9% vs. 89.1%, p = 0.851) analyses. Non-inferiority was confirmed (p < 0.025). A subgroup analysis according to clarithromycin resistance (clarithromycin resistance rate: 28.7%) revealed no significant difference in eradication rates between the 7-day and 14-day STT (90.0% vs. 90.1%, p > 0.99) and BQT (82.5% vs. 86.5%, p = 0.757). Furthermore, adverse events did not significantly differ between the two groups. CONCLUSIONS: The 7-day triple and quadruple therapy according to clarithromycin resistance showed similar eradication rates, as compared to the 14-day therapy.


Asunto(s)
Antibacterianos , Claritromicina , Farmacorresistencia Bacteriana , Infecciones por Helicobacter , Helicobacter pylori , Humanos , Infecciones por Helicobacter/tratamiento farmacológico , Infecciones por Helicobacter/microbiología , Claritromicina/uso terapéutico , Claritromicina/farmacología , Helicobacter pylori/efectos de los fármacos , Helicobacter pylori/genética , Masculino , Femenino , Antibacterianos/uso terapéutico , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antibacterianos/farmacología , Persona de Mediana Edad , Adulto , Estudios Prospectivos , Quimioterapia Combinada , Anciano , Resultado del Tratamiento , Rabeprazol/uso terapéutico , Rabeprazol/administración & dosificación , Bismuto/uso terapéutico , Bismuto/administración & dosificación , ARN Ribosómico 23S/genética
20.
Int J Infect Dis ; 145: 107074, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38734057

RESUMEN

OBJECTIVES: The prevalence of respiratory infectious diseases has changed in the post-COVID-19 epidemic era, and mycoplasma pneumoniae (MP) infection in children has attracted wide attention. METHODS: Children hospitalized for pneumonia in Wuhan, China, in 2023 were enrolled. Respiratory secretions were obtained for the targeted next-generation sequencing (tNGS) including mutation of MP. Pulmonary inflammation was divided into bronchopneumonia and pulmonary consolidation/atelectasis according to lung computed tomography imaging. RESULTS: Of the 667 pediatric pneumonia, 478 were MP positive (72%). The positive rate of MP detected by tNGS increased from April, and MP had become the primary pathogen of pneumonia in children in 2023. The 23S rRNA mutations were all A2063G, accounting for 85% of detected MP. The clinical symptoms of the mutant and wild-type strains were similar, with half of them experiencing atelectasis and lung consolidation. Early bronchoscopic lavage combined with azithromycin in pediatric pulmonary consolidation was an effective therapy strategy, which could be an alternative selection to MP pneumonia treatment. CONCLUSIONS: A2063G mutant strain MP was the primary pathogen of mycoplasma pneumoniae in children recently, which was often complicated by extra-pulmonary symptoms and complications.


Asunto(s)
Mutación , Mycoplasma pneumoniae , Neumonía por Mycoplasma , Humanos , Neumonía por Mycoplasma/epidemiología , Neumonía por Mycoplasma/microbiología , China/epidemiología , Mycoplasma pneumoniae/genética , Mycoplasma pneumoniae/aislamiento & purificación , Femenino , Niño , Masculino , Preescolar , Lactante , ARN Ribosómico 23S/genética , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Azitromicina/uso terapéutico , COVID-19/epidemiología , Secuenciación de Nucleótidos de Alto Rendimiento , Adolescente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...